Table 1 Demographics and clinical characteristics
Patient | Gender | Age (Years) | Localisation | VRS | AF | Medication | Duration of pain | Concomitant permanent pain | Nerve-vessel-conflict | Disease (Years) |
|---|---|---|---|---|---|---|---|---|---|---|
1* | f | 68 | V2 + V3; left | 7 | 25 | Doxepin/Carbamazepin | Min | YES | NO | 6 |
2 | f | 77 | V1; right | 8 | 8 | Gabapentin | Sec | NO | YES | 14 |
3 | f | 53 | V3; right | 6 | 5 | Carbamazepin/Pregabalin | Sec | NO | YES | 20 |
4 | f | 50 | V3; left | 8 | 50 | Oxcarbamazepin/Amitriptylin/Topamax | Sec | NO | NO | 12 |
5 | m | 82 | V1; left | 8 | 3 | Pregabalin/Duloxetin | Min | NO | NO | 25 |
6 | m | 68 | V3; right | 3 | 5 | Morphin/Pregabalin/ | Min | NO | YES | 20 |
7 | f | 78 | V1; left | 6 | 7 | Amitriptylin/Tramal/Pregabalin | Min | YES | YES | 15 |
8 | f | 65 | V2 + V3; left | 5 | 1 | Carbamazepin/Pregabalin/Oxycodon | Min | YES | NO | 21 |
9* | m | 67 | V2; right | 5 | 1 | Gabapentin/Oxcarbazepin/TrimipraMin | Min | NO | NO | 4 |
10* | f | 32 | V2 + V3; left | 8 | 15 | Gabapentin/Oxcarbazepin | Min | NO | YES | 8 |
11* | m | 49 | V2; right | 7 | 8 | Gabapentin/Fluoxetin | Min | YES | NO | 27 |
12* | f | 67 | V2 + V3; right | 7 | 7 | Pregabalin/TrimipraMin | Min | YES | NO | 2 |
13* | m | 77 | V2 + V3; left | 5 | 4 | Gabapentin/Sertralin | Sec | NO | YES | 3 |
14* | f | 34 | V3; left | 8 | 6 | Gabapentin | Min | NO | YES | 2 |
15* | f | 52 | V2 + V3; left | 8 | 8 | Carbamazepin/Oxycodon/Nortriptylin | Sec | YES | NO | 8 |
16* | m | 71 | V3; right | 5 | 4 | Carbamazepin | Sec | NO | NO | 7 |
17* | m | 70 | V2; left | 4 | 5 | Ibuprofen | Sec | NO | YES | 27 |